Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • maf5
    Junior Member
    • Jun 2016
    • 2

    #1

    Binary methylation states after bisulfite sequencing

    Hi everyone. I have sequencing data (illumina Hiseq) from bisulfite treated samples (Arabidopsis). The bisulfite conversion of some selected regions was tested by sanger sequencing initially and looked fine. The library was then made from the same samples using the Diagenode microplex kit.

    Here's the problem: almost all of the cytosines show either total, or zero methylation levels. There are very few (<1%) that show any intermediate levels of methylation. Even on the regions that were already tested by sanger sequencing, which showed a complete range of methylation levels from 0 to 100%.

    So, does anyone know how this bias can come about. My suspicion is that it is either due to an amplification bias when making the libraries, or something in the bioinformatics pipeline. Has anyone experienced similar results from bisulfite sequencing?

    Cheers
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    How were the samples mapped? I can't really debug issues with the library prep (I'm sure someone else here can), but at least the downstream stuff I can offer advice on.

    Comment

    • nucacidhunter
      Jafar Jabbari
      • Jan 2013
      • 1250

      #3
      Originally posted by maf5 View Post
      Hi everyone. I have sequencing data (illumina Hiseq) from bisulfite treated samples (Arabidopsis). The bisulfite conversion of some selected regions was tested by sanger sequencing initially and looked fine. The library was then made from the same samples using the Diagenode microplex kit.
      Cheers
      I assume you are referring to whole genome bisulfite sequencing and wonder how you have made a library with bisulfite converted DNA. The kit input is dsDNA while BS converted DNA will be single stranded.

      Comment

      • maf5
        Junior Member
        • Jun 2016
        • 2

        #4
        Thanks for the replies, it's taken a little time for me to get the details from our bioinformatician.

        The library was pair-end sequenced. To increase the coverage, I mapped each of the mates as independent libraries. I used bowtie2 to map against the in-silico bisulfite-converted TAIR10 genome. I use a seed length of 25 and allowed at most one mismatch in the seed. If a read maps to multiple positions, I keep only the best alignment in terms of quality and numbers of mismatches.
        Using the mapping information I then remove duplicates.

        Regarding the library preparation, the bisulfite treatment was performed on non-denatured DNA so the majority of the genome would have actually remained double stranded (we are not actually looking for methylation in this case) but the library prep worked fine with the diagenode kit, although with quite a few amplification rounds, which is why I suspect it may be an amplification bias

        Comment

        • GenoMax
          Senior Member
          • Feb 2008
          • 7142

          #5
          The library was pair-end sequenced. To increase the coverage, I mapped each of the mates as independent libraries.
          How is that going to increase coverage?

          Comment

          • dpryan
            Devon Ryan
            • Jul 2011
            • 3478

            #6
            The bioinformatician must be rather new to things. Please advise him/her to not try needlessly reinventing the wheel and instead use bwa-meth or bismark or one of the many preexisting alignment programs. It's incredibly likely that he/she simply screwed things up.

            Edit: Forgot an important "not" above!
            Last edited by dpryan; 08-15-2016, 11:55 AM.

            Comment

            • ecSeq Bioinformatics
              Senior Member
              • May 2012
              • 494

              #7
              DNA Methylation Data Analysis Workshop
              How to use bisulfite-treated sequencing to study DNA methylation

              When?
              22. - 25. November 2016

              Where?
              Leipzig, Germany

              Link?


              ecSeq Bioinformatics is Europe’s leading provider of hands-on bioinformatics workshops and professional data analysis in the field of Next-Generation Sequencing (NGS).

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Today, 02:55 AM
              0 responses
              2 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-24-2026, 12:17 PM
              0 responses
              10 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-23-2026, 11:41 AM
              0 responses
              11 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-20-2026, 11:10 AM
              0 responses
              23 views
              0 reactions
              Last Post SEQadmin2  
              Working...